Larimar Therapeutics, Inc. financial data

Symbol
LRMR on Nasdaq
Location
Bala Cynwyd, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 583% % -54%
Debt-to-equity 23% % 114%
Return On Equity -92% % -156%
Return On Assets -75% % -130%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85,590,392 shares 34%
Common Stock, Shares, Outstanding 85,590,392 shares 34%
Entity Public Float $313,608,353 USD
Common Stock, Value, Issued $86,000 USD 34%
Weighted Average Number of Shares Outstanding, Basic 78,324,767 shares 23%
Weighted Average Number of Shares Outstanding, Diluted 78,324,767 shares 23%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $121,589,000 USD 113%
General and Administrative Expense $18,183,000 USD 9.7%
Operating Income (Loss) $139,772,000 USD -89%
Nonoperating Income (Expense) $7,773,000 USD -13%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $131,999,000 USD -104%
Earnings Per Share, Basic -1 USD/shares -71%
Earnings Per Share, Diluted -1 USD/shares -71%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $90,140,000 USD 157%
Cash, Cash Equivalents, and Short-term Investments $175,400,000 USD -14%
Assets, Current $183,223,000 USD -14%
Property, Plant and Equipment, Net $709,000 USD -9%
Operating Lease, Right-of-Use Asset $2,270,000 USD -25%
Other Assets, Noncurrent $542,000 USD -13%
Assets $187,350,000 USD -14%
Accounts Payable, Current $11,100,000 USD 558%
Employee-related Liabilities, Current $3,222,000 USD 36%
Accrued Liabilities, Current $32,865,000 USD 142%
Liabilities, Current $45,116,000 USD 177%
Operating Lease, Liability, Noncurrent $3,196,000 USD -26%
Liabilities $48,312,000 USD 134%
Accumulated Other Comprehensive Income (Loss), Net of Tax $66,000 USD -82%
Retained Earnings (Accumulated Deficit) $372,333,000 USD -55%
Stockholders' Equity Attributable to Parent $139,038,000 USD -30%
Liabilities and Equity $187,350,000 USD -14%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $26,540,000 USD -155%
Net Cash Provided by (Used in) Financing Activities $162,151,000 USD
Net Cash Provided by (Used in) Investing Activities $14,448,000 USD
Common Stock, Shares Authorized 115,000,000 shares 0%
Common Stock, Shares, Issued 85,590,392 shares 34%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $12,092,000 USD -115%
Deferred Tax Assets, Valuation Allowance $173,028,000 USD 22%
Deferred Tax Assets, Gross $173,736,000 USD 22%
Operating Lease, Liability $4,347,000 USD -19%
Depreciation $88,000 USD 10%
Payments to Acquire Property, Plant, and Equipment $49,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $132,291,000 USD -105%
Lessee, Operating Lease, Liability, to be Paid $5,288,000 USD -22%
Property, Plant and Equipment, Gross $2,515,000 USD 12%
Operating Lease, Liability, Current $1,151,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,273,000 USD -14%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,478,000 USD -4.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $941,000 USD -35%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,188,000 USD -6.2%
Deferred Tax Assets, Operating Loss Carryforwards $50,177,000 USD 11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $959,000 USD -19%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $7,857,000 USD -5.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%